127 related articles for article (PubMed ID: 22785358)
21. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells.
Chen G; Zeller WJ
Anticancer Res; 1994; 14(4A):1461-7. PubMed ID: 7979172
[TBL] [Abstract][Full Text] [Related]
22. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
23. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
24. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
25. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
26. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
27. Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.
Palanichamy K; Sreejayan N; Ontko AC
J Inorg Biochem; 2012 Jan; 106(1):32-42. PubMed ID: 22112837
[TBL] [Abstract][Full Text] [Related]
28. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
29. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY
Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028
[TBL] [Abstract][Full Text] [Related]
30. [Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
Li Y; Weng DH; Kong FF; Fan LS; Hu Y; Song XH; Xing H; Wang W; Ma D; Wang SX
Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):445-8. PubMed ID: 21029596
[TBL] [Abstract][Full Text] [Related]
31. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
32. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
Toyozumi Y; Arima N; Izumaru S; Kato S; Morimatsu M; Nakashima T
Int J Oncol; 2004 Sep; 25(3):721-8. PubMed ID: 15289875
[TBL] [Abstract][Full Text] [Related]
33. [Comparative study of that synergistic effect of cisplatin combined with compound herbal medicinal prescription for tonic quality and activating blood circulation is on SKOV3 cell proliferation and apoptosis].
Suo YP; Wang BY; Hong Z; Yin RT; Wang DQ; Peng ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jul; 37(4):542-6. PubMed ID: 16909597
[TBL] [Abstract][Full Text] [Related]
34. The interaction between a drug and ultrasound in sonochemotherapy against ovarian cancers.
He H; Yu T; Zhang Y
Ultraschall Med; 2012 Jun; 33(3):275-82. PubMed ID: 21165815
[TBL] [Abstract][Full Text] [Related]
35. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
[TBL] [Abstract][Full Text] [Related]
36. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
Lu YM; Zhang SL; Meng LR; Zhao YY
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
[TBL] [Abstract][Full Text] [Related]
37. Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells.
Marverti G; Guaitoli G; Ligabue A; Frassineti C; Monti MG; Lombardi P; Costi MP
Amino Acids; 2012 Feb; 42(2-3):641-53. PubMed ID: 21814787
[TBL] [Abstract][Full Text] [Related]
38. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
Zhang N; Dai L; Qi Y; Di W; Xia P
Int J Oncol; 2013 Jun; 42(6):2053-9. PubMed ID: 23592281
[TBL] [Abstract][Full Text] [Related]
39. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
Jian W; Xu HG; Chen J; Xu ZX; Levitt JM; Stanley JA; Yang ES; Lerner SP; Sonpavde G
Anticancer Drugs; 2014 Sep; 25(8):878-86. PubMed ID: 24714082
[TBL] [Abstract][Full Text] [Related]
40. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.
Ormerod MG; O'Neill C; Robertson D; Kelland LR; Harrap KR
Cancer Chemother Pharmacol; 1996; 37(5):463-71. PubMed ID: 8599870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]